Omeros Announces New Date for YARTEMLEA® Approval Conference Call

Core Viewpoint - Omeros Corporation announced a revised date for its conference call to discuss the FDA approval of YARTEMLEA® (narsoplimab-wuug), the first therapy approved for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) [1] Group 1 - The conference call is rescheduled to Wednesday, January 7, to ensure broad participation [1] - The change in schedule accommodates shareholders' and investors' holiday plans following the significant milestone of FDA approval [1]